Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years.
Phase of Trial: Phase I
Latest Information Update: 13 Oct 2015
At a glance
- Drugs Influenza A vaccine H5N1-Baxter (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Baxter Healthcare Corporation
- 24 Jul 2009 Actual patient number changed from 420 to 422 as reported by ClinicalTrials.gov.
- 24 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jul 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.